Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ertl

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Metabolism: Clinical and Experimental|August 20, 2013
Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetesTimothy J Sullivan, Zhenhua Miao, Bin N Zhao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2019
Efficacy of Chemokine Receptor Inhibition in Treating IL-36α-Induced Psoriasiform InflammationJames J Campbell, Karen Ebsworth, Linda S Ertl, et al.
Plos One|March 22, 2018
CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)Zhenhua Miao, Linda S Ertl, Dale Newland, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 3, 2019
CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the BloodBin N Zhao, James J Campbell, Catherina L Salanga, et al.
Journal of the American Society of Nephrology : JASN|November 2, 2013
C5a receptor (CD88) blockade protects against MPO-ANCA GNHong Xiao, Daniel J Dairaghi, Jay P Powers, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters, Yu Wang, Nu Lai, et al.
American Journal of Physiology. Renal Physiology|August 30, 2013
CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin miceTimothy Sullivan, Zhenhua Miao, Daniel J Dairaghi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2016
Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cellsIhsan Ekin Demir, Kristina Kujundzic, Paulo L Pfitzinger, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 2, 2012
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complicationsTimothy J Sullivan, Daniel J Dairaghi, Antoni Krasinski, et al.
Plos One|June 7, 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunityKathleen M C Sullivan, Marta Vilalta, Linda S Ertl, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Metabolism: Clinical and Experimental|August 20, 2013
Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetesTimothy J Sullivan, Zhenhua Miao, Bin N Zhao, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 6, 2019
Efficacy of Chemokine Receptor Inhibition in Treating IL-36α-Induced Psoriasiform InflammationJames J Campbell, Karen Ebsworth, Linda S Ertl, et al.
Plos One|March 22, 2018
CCR2 antagonism leads to marked reduction in proteinuria and glomerular injury in murine models of focal segmental glomerulosclerosis (FSGS)Zhenhua Miao, Linda S Ertl, Dale Newland, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 3, 2019
CCR2-Mediated Uptake of Constitutively Produced CCL2: A Mechanism for Regulating Chemokine Levels in the BloodBin N Zhao, James J Campbell, Catherina L Salanga, et al.
Journal of the American Society of Nephrology : JASN|November 2, 2013
C5a receptor (CD88) blockade protects against MPO-ANCA GNHong Xiao, Daniel J Dairaghi, Jay P Powers, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters, Yu Wang, Nu Lai, et al.
American Journal of Physiology. Renal Physiology|August 30, 2013
CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin miceTimothy Sullivan, Zhenhua Miao, Daniel J Dairaghi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2016
Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cellsIhsan Ekin Demir, Kristina Kujundzic, Paulo L Pfitzinger, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 2, 2012
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complicationsTimothy J Sullivan, Daniel J Dairaghi, Antoni Krasinski, et al.
Plos One|June 7, 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunityKathleen M C Sullivan, Marta Vilalta, Linda S Ertl, et al.
Pageof 6